Koshy M, Weiner S J, Miller S T, Sleeper L A, Vichinsky E, Brown A K, Khakoo Y, Kinney T R
University of Illinois, Chicago 60612, USA.
Blood. 1995 Nov 15;86(10):3676-84.
From 1978 to 1988, The Cooperative Study of Sickle Cell Disease observed 3,765 patients with a mean follow-up of 5.3 +/- 2.0 years. One thousand seventy-nine surgical procedures were conducted on 717 patients (77% sickle cell anemia [SS], 14% sickle hemoglobin C disease [SC], 5.7% S beta zero thalassemia, 3% S beta zero + thalassemia). Sixty-nine percent had a single procedure, 21% had two procedures, and the remaining 11% had more than two procedures during the study follow-up. The most frequent procedure was abdominal surgery for cholecystectomy or splenectomy (24% of all surgical procedures, N = 258). Of these, 93% received blood transfusion, and there was no association between preoperative hemoglobin A level and complication rates (except reduction in pain crisis). Overall mortality within 30 days of a surgical procedure was 1.1% (12 deaths after 1,079 surgical procedures). Three deaths were considered to be related to the surgical procedure and/or anesthesia (0.3%). No deaths were reported in patients younger than 14 years of age. Sickle cell diseases (SCD)-related complications after surgery were more frequent in SS patients who received regional compared with general anesthesia (adjusted for risk level of the surgical procedure, patient age, and preoperative transfusion status, P = .058). Non-SCD-related postoperative complications were higher in both SS and SC patients who received regional compared with those who received general anesthesia (P =.095). Perioperative transfusion was associated with a lower rate of SCD-related postoperative complications for SS patients undergoing low-risk procedures (P = .006, adjusted for age and type of anesthesia), with crude rated of 12.9% without transfusion compared with 4.8% with transfusion. In SC patients, preoperative transfusion was beneficial for all surgical risk levels (P = .009). Thus, surgical procedures can be performed safely in patients with SCD.
1978年至1988年期间,镰状细胞病合作研究观察了3765例患者,平均随访时间为5.3±2.0年。对717例患者实施了1079例外科手术(77%为镰状细胞贫血[SS],14%为镰状血红蛋白C病[SC],5.7%为Sβ0地中海贫血,3%为Sβ0+地中海贫血)。在研究随访期间,69%的患者接受了单次手术,21%的患者接受了两次手术,其余11%的患者接受了两次以上手术。最常见的手术是用于胆囊切除术或脾切除术的腹部手术(占所有外科手术的24%,N=258)。其中,93%的患者接受了输血,术前血红蛋白A水平与并发症发生率之间无关联(疼痛危象减轻除外)。外科手术后30天内的总体死亡率为1.1%(1079例外科手术后有12例死亡)。3例死亡被认为与手术和/或麻醉有关(0.3%)。14岁以下患者未报告死亡病例。与全身麻醉相比,接受区域麻醉的SS患者术后镰状细胞病(SCD)相关并发症更为常见(根据手术风险水平、患者年龄和术前输血状态进行调整,P = 0.058)。与接受全身麻醉的患者相比,接受区域麻醉的SS和SC患者非SCD相关术后并发症更高(P = 0.095)。围手术期输血与接受低风险手术的SS患者术后SCD相关并发症发生率较低相关(P = 0.006,根据年龄和麻醉类型进行调整),未输血患者的粗发病率为12.9%,输血患者为4.8%。在SC患者中,术前输血对所有手术风险水平均有益(P = 0.009)。因此,SCD患者可以安全地进行外科手术。